Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity
Advanced Science · 2026
DOI: 10.1002/advs.202515480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Nicolas Marzolini und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Endothelial Cells, DNA, Nanoparticles, Lipids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Library of Medicine under the National Institutes of Health, NIH HHS.
Abstract (Originalsprache)
DNA‐lipid nanoparticles (DNA‐LNPs) loaded with inhibitors of the cGAS‐STING pathway enable safe and effective delivery of DNA in vivo. Herein, we report the first instances of extrahepatic DNA‐LNP targeting. DNA‐LNPs conjugated to antibodies against PECAM‐1 or VCAM‐1 target the endothelium of the lungs and brain/spleen, respectively. These LNPs drive robust transgene expression in their target organs, with greater magnitude and duration than untargeted LNPs. Lung specificity of PECAM‐targeted transgene expression increases over two weeks, resulting in markedly higher lung‐to‐liver expression ratios than our previous PECAM‐targeted mRNA‐LNPs. Off‐target liver DNA expression declines to undetectable levels but persists in the lungs, while mRNA expression uniformly decreases due to its short half‐life. We further improve this expression specificity by replacing full‐length antibodies with Fab fragments. Single‐cell analysis reveals a key mechanism underlying the improvements in organ‐specificity: target organ expression is dominated by long‐lived endothelial cells, while off‐target liver delivery and expression are in non‐endothelial cells with shorter half‐lives. Collectively, these studies demonstrate that targeted DNA‐LNPs achieve high levels of organ‐ and cell‐type‐specific transgene expression and thus provide a therapeutic platform for dozens of endothelial‐centric diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Pulmonary Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Nicolas Marzolini, Taylor V Brysgel, Ryan J Rahman, Eno-Obong Essien, Jichuan Wu, Manthan N Patel, Sachchidanand Tiwari, Carolann L Espy, Sabrina A Santos-De León, Anit Shah, Vladimir V Shuvaev, Elizabeth D Hood, Liam S Chase, Drew Weissman, Jeremy B Katzen, David B Frank, Mariko L Bennett, Oscar A Marcos-Contreras, Jacob W Myerson, Vladimir R Muzykantov, Sahily Reyes-Esteves, Jacob S Brenner
Förderung
- NHLBI NIH HHS
- National Library of Medicine under the National Institutes of Health
- NIH HHS
- American Heart Association
- Abramson Cancer Center NCI
- NCATS NIH HHS
- National Center for Advancing Translational Sciences of the National Institutes of Health
- National Science Foundation under Cooperative Agreement DBI
Zitieren
APA
Marzolini, N., Brysgel, T. V., Rahman, R. J., Essien, E. O., Nwe, S. Y., Wu, J., Majumder, A., Patel, M. N., Tiwari, S., Espy, C. L., Dong, F., Santos-De León, S. A., Shah, A., Shuvaev, V. V., Hood, E. D., Chase, L. S., Weissman, D., Katzen, J. B., Frank, D. B., …, & Brenner, J. S. (2026). Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity. Advanced Science. https://doi.org/10.1002/advs.202515480
Vancouver
Marzolini N, Brysgel TV, Rahman RJ, Essien EO, Nwe SY, Wu J, et al. Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity. Advanced Science. 2026. doi:10.1002/advs.202515480
BibTeX
@article{Marzolini2026,
author = {Marzolini, Nicolas and Brysgel, Taylor V and Rahman, Ryan J and Essien, Eno-Obong and Nwe, Saw Y and Wu, Jichuan and Majumder, Aparajeeta and Patel, Manthan N and Tiwari, Sachchidanand and Espy, Carolann L and Dong, Fengyi and Santos-De León, Sabrina A and Shah, Anit and Shuvaev, Vladimir V and Hood, Elizabeth D and Chase, Liam S and Weissman, Drew and Katzen, Jeremy B and Frank, David B and Bennett, Mariko L and Marcos-Contreras, Oscar A and Myerson, Jacob W and Muzykantov, Vladimir R and Reyes-Esteves, Sahily and Brenner, Jacob S},
title = {Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202515480}
}
EUVIMED